title: In vitro and in vivo characterization of anthrax anti-protective antigen and anti-lethal factor monoclonal antibodies after passive transfer in a mouse lethal toxin challenge model to define correlates of immunity.
abstract: Passive transfer of antibody may be useful for preexposure prophylaxis against biological agents used as weapons of terror, such as Bacillus anthracis. Studies were performed to evaluate the ability of anthrax antiprotective antigen (anti-PA) and antilethal factor (anti-LF) neutralizing monoclonal antibodies (mAbs) to protect against an anthrax lethal toxin (LeTx) challenge in a mouse model and to identify correlates of immunity to LeTx challenge. Despite having similar affinities for their respective antigens, anti-PA (3F11) and anti-LF (9A11), passive transfer of up to 1.5 mg of anti-PA 3F11 mAb did not provide significant protection when transferred to mice 24 h before LeTx challenge, while passive transfer of as low as 0.375 mg of anti-LF 9A11 did provide significant protection. Serum collected 24 h after passive transfer had LeTx-neutralizing activity when tested using a standard LeTx neutralization assay, but neutralization titers measured using this assay did not correlate with protection against LeTx challenge. However, measurement of LeTx-neutralizing serum responses with an LeTx neutralization assay in vitro employing the addition of LeTx to J774A.1 cells 15 min before the addition of the serum did result in neutralization titers that correlated with protection against LeTx challenge. Our results demonstrate that only the LeTx neutralization titers measured utilizing the addition of LeTx to J774A.1 cells 15 min before the addition of sample correlated with protection in vivo. Thus, this LeTx neutralization assay may be a more biologically relevant neutralization assay to predict the in vivo protective capacity of LeTx-neutralizing antibodies.
authors: Department of Pathology, Box 3712, DUMC, Durham, NC 27710, USA. hfs@duke.edu
authors: Herman F
authors: HF
authors: Staats
authors: S Munir
authors: SM
authors: Alam
authors: Richard M
authors: RM
authors: Scearce
authors: Shaun M
authors: SM
authors: Kirwan
authors: Julia Xianzhi
authors: JX
authors: Zhang
authors: William M
authors: WM
authors: Gwinn
authors: Barton F
authors: BF
authors: Haynes
mesh_terms: D000818:Animals; D000881:Anthrax / Q000276:immunology / Q000517:prevention & control*; D000907:Antibodies, Bacterial / Q000276:immunology*; D000911:Antibodies, Monoclonal / Q000276:immunology*; D000915:Antibody Affinity; D000942:Antigens, Bacterial / Q000276:immunology* / Q000633:toxicity; D000992:Antitoxins / Q000276:immunology*; D001408:Bacillus anthracis / Q000276:immunology; D001427:Bacterial Toxins / Q000276:immunology* / Q000633:toxicity; D002460:Cell Line; D002470:Cell Survival; D005260:Female; D007116:Immunization, Passive; D008264:Macrophages / Q000187:drug effects; D051379:Mice; D008807:Mice, Inbred BALB C; D009500:Neutralization Tests
chemical_list: D000907:Antibodies, Bacterial; D000911:Antibodies, Monoclonal; D000942:Antigens, Bacterial; D000992:Antitoxins; D001427:Bacterial Toxins; C030325:anthrax toxin
references: Infect Immun. 2001 May;69(5):2853-7
references: 11292698
references: Vaccine. 2000 Sep 15;19(2-3):213-6
references: 10930675
references: Vaccine. 2001 Apr 30;19(23-24):3241-7
references: 11312020
references: Infect Immun. 2001 Jul;69(7):4509-15
references: 11401993
references: J Hum Virol. 2001 Mar-Apr;4(2):55-61
references: 11437315
references: Vaccine. 2001 Aug 14;19(31):4409-16
references: 11483266
references: Vaccine. 2001 Sep 14;19(32):4768-73
references: 11535328
references: Crit Rev Microbiol. 2001;27(3):167-200
references: 11596878
references: JAMA. 2001 Nov 28;286(20):2549-53
references: 11722268
references: JAMA. 2001 Nov 28;286(20):2554-9
references: 11722269
references: JAMA. 2001 Nov 28;286(20):2595-7
references: 11722275
references: J Virol. 2002 Jan;76(2):517-24
references: 11752142
references: Infect Immun. 2002 Feb;70(2):544-60
references: 11796581
references: Infect Immun. 2002 Feb;70(2):702-7
references: 11796602
references: Nat Biotechnol. 2002 Jun;20(6):597-601
references: 12042864
references: Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11346-50
references: 12177434
references: Emerg Infect Dis. 2002 Oct;8(10):1044-7
references: 12396913
references: Emerg Infect Dis. 2002 Oct;8(10):1048-55
references: 12396914
references: Emerg Infect Dis. 2002 Oct;8(10):1066-72
references: 12396917
references: Emerg Infect Dis. 2002 Oct;8(10):1073-7
references: 12396918
references: Infect Immun. 2003 May;71(5):2373-83
references: 12704107
references: J Immunol. 2003 Jun 1;170(11):5636-43
references: 12759444
references: J Clin Invest. 2003 Sep;112(5):670-82
references: 12952916
references: Nat Biotechnol. 2003 Nov;21(11):1305-6
references: 14555959
references: Vaccine. 2004 Jan 2;22(3-4):422-30
references: 14670324
references: Am J Physiol Regul Integr Comp Physiol. 2004 Apr;286(4):R699-709
references: 14715494
references: Hum Antibodies. 2003;12(4):129-35
references: 15156101
references: Infect Immun. 2004 Jun;72(6):3276-83
references: 15155630
references: AIDS Res Hum Retroviruses. 2004 Aug;20(8):836-45
references: 15320988
references: Infect Immun. 2004 Nov;72(11):6313-7
references: 15501759
references: Diabetes. 1981 Mar;30(3):226-30
references: 7009271
references: Methods Enzymol. 1983;103:459-69
references: 6669042
references: J Exp Med. 1984 Apr 1;159(4):1117-31
references: 6323615
references: J Immunol. 1984 Sep;133(3):1241-9
references: 6205074
references: J Immunol. 1985 Jan;134(1):250-7
references: 2578044
references: J Immunol. 1985 Jul;135(1):247-54
references: 2987346
references: Hybridoma. 1986 Spring;5(1):21-31
references: 2420699
references: Vox Sang. 1987;52(3):236-43
references: 3474823
references: Infect Immun. 1988 Jul;56(7):1807-13
references: 3384478
references: Infect Immun. 1990 Jun;58(6):1606-13
references: 2111283
references: Infect Immun. 1992 Feb;60(2):662-8
references: 1730501
references: Arch Virol. 1992;125(1-4):239-50
references: 1642552
references: AIDS Res Hum Retroviruses. 1997 May 20;13(8):647-56
references: 9168233
references: Infect Immun. 1997 Dec;65(12):5171-5
references: 9393812
references: Vaccine. 1998 Jul;16(11-12):1141-8
references: 9682372
references: J Infect Dis. 2005 Jan 15;191(2):278-88
references: 15609239
references: J Infect Dis. 2005 Feb 1;191(3):422-34
references: 15633102
references: Infect Immun. 2005 Feb;73(2):795-802
references: 15664918
references: Vaccine. 2005 Mar 18;23(17-18):2082-6
references: 15755575
references: Clin Diagn Lab Immunol. 2005 Jun;12(6):713-21
references: 15939745
references: Infect Immun. 2005 Oct;73(10):6547-51
references: 16177329
references: Infect Immun. 2005 Dec;73(12):8362-8
references: 16299334
references: J Pharm Sci. 2006 Jan;95(1):80-96
references: 16315230
references: Infect Immun. 2006 Jan;74(1):794-7
references: 16369043
references: Vaccine. 2006 May 1;24(18):3953-63
references: 16530302
references: AIDS Res Hum Retroviruses. 2006 Jun;22(6):558-68
references: 16796531
references: Vaccine. 2006 Sep 29;24(40-41):6405-13
references: 16828937
references: J Immunol. 2007 Apr 1;178(7):4424-35
references: 17372000
references: Infect Immun. 2001 May;69(5):2888-93
references: 11292703